What Should US Policymakers Learn From International Drug Pricing Transparency Strategies?

Nagar, Sarosh; Rand, Leah; Kesselheim, Aaron S.

doi:10.1001/amajethics.2022.1083

Cited by 2 publications

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Being a more of an insurance-based and capitalistic model, the healthcare system in the US has moved away from being more of a patient-centric societal model. There is no doubt that all countries can learn from each other when it comes to transparency in pricing, particularly when it comes to price transparency in the US healthcare system (Nagar et al, 2022).…”

Section: Prescription Drug Pricing-lack Of Transparencymentioning

confidence: 99%

Issues and Challenges Pertaining to Financing in Providing Pricing Transparency in the American Health Care Industry

Willis

Chandra

Sodani

2023

Journal of Health Management

View full text Add to dashboard Cite

In January 2021, hospitals and payer-specific entities in the United States were mandated to comply with the new pricing transparency rules. These rules applied to all standard charges a hospital applied to services provided to and for a consumer. From a financial perspective, the issue of price transparency in health care has for several decades surfaced as a legitimate concern of consumers, health care providers and payers. The aim of this article is to historically examine where and how pricing in health care began and to illustrate financial issues leading up to the current transparency in pricing required by health care payers and providers. A comparative analysis of issues and challenges pertaining to the transparency in pharmaceutical product pricing between the United States and India is also provided in brief.

show abstract

Section: Prescription Drug Pricing-lack Of Transparencymentioning

confidence: 99%